AI assistant
Biocon Ltd. — Regulatory Filings 2021
Apr 12, 2021
61176_rns_2021-04-12_57950232-dc16-48a3-9d6d-630873efb0c5.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [132 x 52] intentionally omitted <==
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com
April 12, 2021
| To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001 |
To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 |
|---|---|
| Scrip Code - 532523 | Scrip Symbol - Biocon |
Subject: Company Statement
Dear Sir/Madam,
Please find below a Company Statement titled “Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK.”
“This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines & Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru.
The certificate, which includes manufacturing and packaging of tablets and capsules in the non-potent and potent blocks of the facility, was issued based on a remote inspection in the week of 22nd March, 2021, in the wake of travel restrictions amidst Covid-19.”
The above information will also be available on the website of the Company at www.biocon.com.
Kindly take the same on record and acknowledge.
Thanking You,
Yours faithfully,
For Biocon Limited
MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2021.04.12 08:21:33 +05'30' ___
Mayank Verma Company Secretary and Compliance Officer